Keywords: lilly, pays, 35m, tp, osteoperosis, patch, drug
Lilly pays $35M for TP's osteoperosis patch
Article | 23 June 2008
US drug major Eli Lilly has entered into a licensing and development agreement for Israel-based TransPharma Medical's transdermal osteoperosis treatment.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
